All In MedTech

FDA Clearance Tracker · P960011-S009

BIOLON (1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERY)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 27, 2005 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 27, 2005

Approved

Time to decision

202 days

Received Jul 9, 2004. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P960011-S009
Device name
BIOLON (1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERY)
Applicant location
Theale
Received
Jul 9, 2004
Decided
Jan 27, 2005
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P960011

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A CHANGE IN MANUFACTURING SITE TO THE BIO-TECHNOLOGY GENERAL, LTD. FACILITY IN BE'ER TUVIA, ISRAEL, AND FOR A CHANGE IN THE SPECIFICATIONS FOR THE ACTIVE PHARMACEUTICAL PRODUCT IN BIOLON.

Source documents

Other decisions for Altacor , Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.